Clinical impact of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status on recurrence patterns and the efficacy of local therapy after hepatectomy for colorectal liver metastases
Surgery Today · 2026-10 · 56 (10) · 2447-2455
DOI: 10.1007/s00595-026-03377-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgery Today, online erschienen am 01.07.2026. Verfasst von Kosuke Kanemitsu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Kumamoto Chuo-ku, Kumamoto, 860-85…. Hauptthemen laut MEDLINE: Liver Neoplasms, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Hepatectomy. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
PURPOSES: The Kirsten rat sarcoma viral oncogene homolog (KRAS) is defined as frequently mutated oncogenes in colorectal cancer. We aimed to clarify the clinical impact of KRAS mutation status on recurrence patterns, the surgical management of recurrent lesions, and prognostic outcomes after curative hepatectomy for colorectal liver metastases (CRLM). METHODS: The subjects of this retrospective study were 190 patients who underwent curative (macroscopic R0 resection) hepatectomy for CRLM and had wild-type (62.1%) or mutant (37.9%) KRAS status. RESULTS: KRAS mutations were associated with significantly worse overall survival (OS) and recurrence-free survival (RFS), as well as more aggressive recurrence patterns. Multivariate analysis identified KRAS mutation as an independent predictor of poor OS and RFS, whereas CEA ≥ 5 ng/mL was independently associated with OS but not RFS. Notably, patients from the mutant KRAS and wild-type KRAS groups who underwent local therapy (as repeat resection or ablation) for local recurrence had comparable OS. Conversely, among the patients who did not receive local therapy, those from the mutant KRAS group had significantly worse OS than those from the wild-type KRAS group. CONCLUSIONS: KRAS mutations are associated with aggressive recurrence patterns and a poor prognosis for patients with CRLM. However, survival following local therapy for recurrence appeared less pronounced regardless of KRAS status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Kumamoto Chuo-ku, Kumamoto, 860-8556, Japan.
- Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Kumamoto Chuo-ku, Kumamoto, 860-8556, Japan. hhayasi@kumamoto-u.ac.jp.
Zitieren
APA
Kanemitsu, K., Hayashi, H., Tagayasu, Y., Tanizaki, T., Adachi, Y., Ofuchi, T., Tajiri, T., Kitano, Y., Okabe, H., & Iwatsuki, M. (2026). Clinical impact of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status on recurrence patterns and the efficacy of local therapy after hepatectomy for colorectal liver metastases. Surgery Today, 56(10), 2447-2455. https://doi.org/10.1007/s00595-026-03377-y
Vancouver
Kanemitsu K, Hayashi H, Tagayasu Y, Tanizaki T, Adachi Y, Ofuchi T, et al. Clinical impact of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status on recurrence patterns and the efficacy of local therapy after hepatectomy for colorectal liver metastases. Surgery Today. 2026;56(10):2447-2455. doi:10.1007/s00595-026-03377-y
BibTeX
@article{Kanemitsu2026,
author = {Kanemitsu, Kosuke and Hayashi, Hiromitsu and Tagayasu, Yoshiyuki and Tanizaki, Takumi and Adachi, Yuki and Ofuchi, Takashi and Tajiri, Takuya and Kitano, Yuki and Okabe, Hirohisa and Iwatsuki, Masaaki},
title = {Clinical impact of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status on recurrence patterns and the efficacy of local therapy after hepatectomy for colorectal liver metastases},
journal = {Surgery Today},
year = {2026},
volume = {56},
number = {10},
pages = {2447--2455},
doi = {10.1007/s00595-026-03377-y}
}
EUVIMED